Tune Therapeutics Reveals Epigenetic Editing Program…

LEAD Therapeutics, Inc., a chemistry-driven drug discovery company based in the San Francisco Bay Area, today announced it has entered into a strategic research collaboration with Shanghai ChemPartner in China, the wholly owned subsidiary of ShangPharma. In conjunction with this collaboration, China Gateway Life Science (Holding) Ltd., the strategic investment arm of ShangPharma, has made an equity investment in LEAD Therapeutics. Previously announced investors include Pappas Ventures, ProQuest Investments, and Mustang Ventures.